For example, the knock-down of SNX1 increased EGF-induced EGFR degradation in human gefitinib-resistant lung cancer cell line [26], yet no effect on EGF-mediated EGFR degradation was reported upon the knock-down of SNX1 and SNX2 [27]. This evidence concerns the gene SNX1 and lung carcinoma.